UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________________________________________
FORM 8-K
____________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 1, 2020
__________________________________________________________________________________________
(Exact Name of Registrant as Specified in its Charter)
____________________________________________________________________________________________
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) | ||||||
(Address of principal executive offices and zip code)
(267 ) 364-3500
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
____________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) | |||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
| Emerging growth company | |||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||||||||
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On December 1, 2020, the Board of Directors (the "Board") of OptiNose, Inc. (the “Company”) appointed Tomas J. Heyman as a member of the Board. Mr. Heyman was appointed as a Class I director, with an initial term expiring at the 2021 annual meeting of stockholders.
Mr. Heyman will be compensated for his service on the Board in accordance with the Company’s non-employee director compensation policy. Additionally, Mr. Heyman entered into the Company's standard indemnification agreement for directors and officers, the form of which was filed as an exhibit to the Company's registration statement on Form S-1 (Registration No. 333-220515), and will be covered by the Company’s directors' and officers' insurance policy.
There is no arrangement or understanding between Mr. Heyman and any other person pursuant to which Mr. Heyman was appointed as a director. Except as described herein, there are no existing or currently proposed transactions to which the Company or any of its subsidiaries is a party and in which Mr. Heyman has a direct or indirect material interest.
Additionally, effective as the close of the regularly scheduled Board meeting to be held on December 11, 2020, Mr. William F. Doyle will be resigning from the Board and as a member of the Board’s Nominating & Corporate Governance committee. Mr. Doyle’s resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. The Company thanks Mr. Doyle for his service and valuable contributions to the Company.
Item 7.01 Regulation FD Disclosure.
On December 1, 2020, the Company issued a press release announcing the appointment of Thomas J. Heyman to the Company's Board of Directors and the resignation of William F. Doyle from the Board. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
* * *
The information included in Item 7.01 (including Exhibit 99.1) of this Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any Company filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit | Description | |||||||
| 99.1 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| OptiNose, Inc. | ||||||||
| By: /s/ Keith A. Goldan | ||||||||
| Keith A. Goldan | ||||||||
| Chief Financial Officer | ||||||||
Date: December 1, 2020
Exhibit 99.1
Optinose Announces Changes to Board of Directors
YARDLEY, Pa., Dec. 1, 2020— Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Tomas J. Heyman as a new director.
Tom has a long-standing track record of leadership and management in the biopharmaceutical industry, with extensive experience in business development and venture capital. During his thirty-seven-year career with Johnson & Johnson, he held a diverse range of leadership roles across legal, R&D, business development, general corporate management, and equity investments. Most recently, he served as president of JJDC, the venture capital group within Johnson & Johnson, where he managed approximately $1.5 billion of capital and oversaw investments in more than 120 companies.
Prior to leading JJDC, he led business development for Johnson & Johnson's pharmaceutical group, Janssen, for twenty-three years. Under his leadership the group completed hundreds of licensing and M&A transactions including the acquisitions of Centocor, Tibotec, Cougar Pharmaceuticals, and Aragon Pharmaceuticals. In addition, he currently serves on the Board of Directors for Akero Therapeutics.
Tom graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.
"We are pleased to welcome Tom to the Optinose Board of Directors," stated Joe Scodari, Chairman of the Optinose Board. "His extraordinary experience in business development, and more broadly as a leader in the pharmaceutical industry, will make him a valuable addition to our Board of Directors."
In addition, the Company also announced that William F. Doyle, who has served on the Optinose Board of Directors since 2010, and previously as a member of the OptiNose AS Board of Directors from 2004 to 2010, intends to resign following a regularly scheduled Board meeting to be held on December 11, 2020.
"On behalf of Optinose I would like to thank Bill for his significant contributions as a member of our Board," said Mr. Scodari. "Bill was instrumental in bringing about the significant change in strategic direction for Optinose that led to the development of two FDA-approved products using its proprietary Exhalation Delivery System, and in building an organization focused on serving the needs of patients cared for by ear, nose and throat and allergy specialists."
“It has been a privilege to work with the Optinose founders and management to develop their Exhalation Delivery System and to commercialize the XHANCE® (fluticasone propionate) therapy,” said Bill Doyle. “I am highly confident in the efficacy of XHANCE and that there is a tremendous opportunity ahead for Optinose to reach the millions of new patients who can benefit from XHANCE treatment. I congratulate Tom Heyman for joining the Optinose board and look forward to providing continued assistance in a non-board capacity.”
About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
###